BR112015000474A2 - antibody composition for the prevention or treatment of hepatitis b mutant virus infection - Google Patents
antibody composition for the prevention or treatment of hepatitis b mutant virus infectionInfo
- Publication number
- BR112015000474A2 BR112015000474A2 BR112015000474A BR112015000474A BR112015000474A2 BR 112015000474 A2 BR112015000474 A2 BR 112015000474A2 BR 112015000474 A BR112015000474 A BR 112015000474A BR 112015000474 A BR112015000474 A BR 112015000474A BR 112015000474 A2 BR112015000474 A2 BR 112015000474A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- virus
- mutant
- antibody
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
resumo composiìo de anticorpo para a prevenìo ou tratamento de infecìo por vêrus mutante da hepatite b, provendo um anticorpo que se liga ao antgeno de superfcie (hbsag) do vrus da hepatite b (hbv) para neutralizar o vrus da hepatite b. o stio de ligao ao antgeno de superfcie do anticorpo demonstrou desempenhar um papel muito importante na replicao viral, e quando uma mutao no stio ocorre, a replicao viral significativamente inibida, e, assim, pelo menos o vrus hbv no pode causar uma mutao no stio. na presente inveno, foi confirmado pelo uso de um vrus derivado de paciente que o anticorpo da presente inveno se liga ao vrus mutante ymdd da hepatite b, produzido por inibidores de replicao viral convencionais, ou mutantes g145r hbsag aos quais hbig derivado de plasma (imunoglobulina de hepatite b) no se ligam. o anticorpo da presente inveno tem a capacidade para se ligar no apenas ao vrus da hepatite b tipo selvagem, mas ainda, vrus mutantes da hepatite b tendo um mutante ymdd de polimerase e uma mutao g145r de antgeno de superfcie, bem como vrios vrus mutantes derivados de pacientes. o anticorpo da presente inveno pode ser efetivamente usado para a preveno ou tratamento de infeces com no apenas vrus da hepatite b tipo selvagem, mas, alm disso, vrus mutantes da hepatite b. 1/1abstract antibody composition for the prevention or treatment of hepatitis b mutant virus infection, providing an antibody that binds to the surface antigen (hbsag) of the hepatitis b virus (hbv ) to neutralize hepatitis b virus. The surface antigen binding site of the antibody has been shown to play a very important role in viral replication, and when a mutation in the site occurs, viral replication It is significantly inhibited, and thus at least the hbv virus cannot cause a mutation at the site. in the present invention, it was confirmed by the use of a patient-derived virus that the antibody of the present invention binds to the ymdd mutant hepatitis b virus produced by conventional viral replication inhibitors. , or g145r hbsag mutants to which plasma-derived hbig (hepatitis b immunoglobulin) do not bind. The antibody of the present invention has the ability to bind not only wild-type hepatitis B virus, but also mutant hepatitis B virus having a polymerase ymdd mutant and a mutant surface antigen g145r, as well as several patient-derived mutant viruses. The antibody of the present invention can be effectively used for the prevention or treatment of infections with not only wild-type hepatitis B virus but, in addition, mutant viruses of hepatitis b. 1/1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120075063 | 2012-07-10 | ||
| PCT/KR2013/006025 WO2014010890A1 (en) | 2012-07-10 | 2013-07-08 | An antibody composition for prevention or treatment of mutant hepatitis b virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015000474A2 true BR112015000474A2 (en) | 2017-11-14 |
Family
ID=49916280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015000474A BR112015000474A2 (en) | 2012-07-10 | 2013-07-08 | antibody composition for the prevention or treatment of hepatitis b mutant virus infection |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9683029B2 (en) |
| EP (1) | EP2858674B1 (en) |
| JP (2) | JP6113279B2 (en) |
| KR (2) | KR20160092042A (en) |
| CN (2) | CN107375924A (en) |
| AU (1) | AU2013287516B2 (en) |
| BR (1) | BR112015000474A2 (en) |
| CA (1) | CA2878155C (en) |
| EA (1) | EA029321B1 (en) |
| ES (1) | ES2712686T3 (en) |
| HR (1) | HRP20190393T1 (en) |
| MX (1) | MX363256B (en) |
| MY (1) | MY178496A (en) |
| WO (1) | WO2014010890A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106565840B (en) * | 2015-10-09 | 2020-09-01 | 厦门大学 | Antibody against hepatitis B surface antigen and use thereof |
| CN108624564A (en) * | 2017-03-17 | 2018-10-09 | 艾博生物医药(杭州)有限公司 | The preparation and screening of the grand antibody of monoclonal antibody of anti-hepatitis B surface antigen |
| CN108624565A (en) * | 2017-03-17 | 2018-10-09 | 艾博生物医药(杭州)有限公司 | A kind of grand Antibody preparation of monoclonal antibody of anti-hepatitis B surface antigen and screening |
| CN107132357B (en) * | 2017-03-23 | 2019-11-01 | 山东大学 | A kind of combination and application of the anti-Tim-3 antibody and α-galcer reversing Chronic Hepatitis B Virus infection |
| CN107648602B (en) * | 2017-10-23 | 2020-09-01 | 苏州大学 | Bivalent hepatitis B vaccine and preparation method thereof |
| HRP20231338T1 (en) * | 2018-12-20 | 2024-02-16 | Vir Biotechnology, Inc. | Combination hbv therapy |
| KR20220117627A (en) * | 2021-02-17 | 2022-08-24 | 주식회사 녹십자 | A Composition for Treatment of Hepatitis B Comprising HBV Specific Antibody for Combination with Vaccine Composition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9007024D0 (en) * | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
| FR2815634B1 (en) * | 2000-10-20 | 2003-10-31 | Biomerieux Sa | MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUSES |
| KR100467706B1 (en) * | 2002-01-15 | 2005-01-24 | 주식회사 녹십자홀딩스 | Human antibodies against the surface antigen of HBV |
| JP4502642B2 (en) * | 2002-02-07 | 2010-07-14 | メルボルン ヘルス | Virus variants with altered susceptibility to nucleoside analogues and uses thereof |
| US7405039B2 (en) * | 2002-02-07 | 2008-07-29 | Austin Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| EP1499712A4 (en) | 2002-04-12 | 2008-04-16 | Melbourne Health | Hepatitis b viral variants with reduced susceptibility to nucleoside analogs and uses thereof |
| CN1600856A (en) * | 2003-09-26 | 2005-03-30 | 陕西九州科技股份有限公司 | Method for constructing hybridoma cell line of heterogeneity of seereting human monoclonal antibody for anti hepatitis B |
| US7785595B2 (en) * | 2005-04-18 | 2010-08-31 | Yeda Research And Development Company Limited | Stabilized anti-hepatitis B (HBV) antibody formulations |
| KR20090056543A (en) * | 2007-11-30 | 2009-06-03 | 주식회사 녹십자 | Pharmaceutical formulation comprising hepatitis b virus neutralizing human antibody |
| KR20090056537A (en) * | 2007-11-30 | 2009-06-03 | 주식회사 녹십자 | Composition comprising a human antibody capable of neutralizing hepatitis b virus for preventing or treating hepatitis b virus infection |
| KR101072895B1 (en) * | 2009-12-24 | 2011-10-17 | 주식회사 녹십자 | Human antibodies specifically binding to the Hepatitis B virus surface antigen |
-
2013
- 2013-07-08 MX MX2015000349A patent/MX363256B/en unknown
- 2013-07-08 CA CA2878155A patent/CA2878155C/en active Active
- 2013-07-08 EP EP13817251.5A patent/EP2858674B1/en active Active
- 2013-07-08 ES ES13817251T patent/ES2712686T3/en active Active
- 2013-07-08 KR KR1020167020151A patent/KR20160092042A/en not_active Application Discontinuation
- 2013-07-08 JP JP2015521540A patent/JP6113279B2/en not_active Expired - Fee Related
- 2013-07-08 CN CN201710364576.XA patent/CN107375924A/en active Pending
- 2013-07-08 BR BR112015000474A patent/BR112015000474A2/en active Search and Examination
- 2013-07-08 MY MYPI2015000053A patent/MY178496A/en unknown
- 2013-07-08 AU AU2013287516A patent/AU2013287516B2/en not_active Ceased
- 2013-07-08 CN CN201380036814.4A patent/CN104487090B/en active Active
- 2013-07-08 WO PCT/KR2013/006025 patent/WO2014010890A1/en active Application Filing
- 2013-07-08 EA EA201500114A patent/EA029321B1/en not_active IP Right Cessation
- 2013-07-08 KR KR1020157000623A patent/KR101653261B1/en active IP Right Grant
- 2013-07-08 US US14/412,138 patent/US9683029B2/en active Active
-
2017
- 2017-01-20 JP JP2017008118A patent/JP2017095504A/en active Pending
- 2017-05-16 US US15/596,081 patent/US20170260257A1/en not_active Abandoned
-
2019
- 2019-02-28 HR HRP20190393TT patent/HRP20190393T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014010890A1 (en) | 2014-01-16 |
| JP6113279B2 (en) | 2017-04-12 |
| CN104487090B (en) | 2017-06-16 |
| KR20150029699A (en) | 2015-03-18 |
| US20170260257A1 (en) | 2017-09-14 |
| US20150166637A1 (en) | 2015-06-18 |
| KR20160092042A (en) | 2016-08-03 |
| ES2712686T3 (en) | 2019-05-14 |
| HRP20190393T1 (en) | 2019-04-19 |
| EP2858674A4 (en) | 2015-12-23 |
| KR101653261B1 (en) | 2016-09-12 |
| MX363256B (en) | 2019-03-19 |
| EP2858674A1 (en) | 2015-04-15 |
| MX2015000349A (en) | 2015-09-29 |
| JP2015527317A (en) | 2015-09-17 |
| AU2013287516A1 (en) | 2015-01-29 |
| EA029321B1 (en) | 2018-03-30 |
| US9683029B2 (en) | 2017-06-20 |
| CA2878155A1 (en) | 2014-01-16 |
| AU2013287516B2 (en) | 2016-07-07 |
| EA201500114A1 (en) | 2015-05-29 |
| JP2017095504A (en) | 2017-06-01 |
| EP2858674B1 (en) | 2019-01-30 |
| CA2878155C (en) | 2019-01-08 |
| CN104487090A (en) | 2015-04-01 |
| MY178496A (en) | 2020-10-14 |
| CN107375924A (en) | 2017-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015000474A2 (en) | antibody composition for the prevention or treatment of hepatitis b mutant virus infection | |
| BR112018002406A2 (en) | antibodies that potently neutralize the hepatitis b virus and their uses | |
| BR112018009009A2 (en) | combined therapy of an hbv capsid formation inhibitor and an interferon | |
| MX2012001592A (en) | Composition for treating hbv infection. | |
| BR112019004560A2 (en) | combination treatment with tlr7 agonist and a hbv capsid formation inhibitor | |
| PE20140844A1 (en) | YEAST-BASED THERAPEUTICS FOR CHRONIC HEPATITIS B INFECTION | |
| BR112015027369A2 (en) | compositions and methods for modulating the expression of hbv and ttr | |
| BRPI0911699B8 (en) | vector, cell, pharmaceutical composition, use of an antibody, or antigen-binding fragment thereof | |
| BR112018071048A2 (en) | combinations and methods comprising a capsid assembly inhibitor | |
| BR112021011858A2 (en) | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections | |
| BR112015021341A2 (en) | flavivirus neutralizing antibodies and methods of use | |
| BR112018000771A2 (en) | antibodies that bind to sortilin and inhibit progranulin binding, pharmaceutical compositions, preparations thereof, use of antibodies, kit and method for preventing or treating a disease associated with decreased levels of pgrn | |
| EA202191736A1 (en) | HBV COMBINATION THERAPY | |
| MY163742A (en) | Epitope and its use of hepatitis b virus surface antigen | |
| CU20190013A7 (en) | COMPOSITIONS OF MULTIVALENT VACCINES | |
| EA201890362A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE ADDITION OF EDUCATION OF THE HKVD VIRUS OF HEPATITIS B VIRUS | |
| MX2020001226A (en) | A composition for treating and/or preventing hepatitis b virus infection and the use thereof. | |
| MA40844A (en) | LONG-ACTING PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C | |
| BR112022010425A2 (en) | INTERFERON-ASSOCIATED ANTIGEN-BINDING PROTEINS FOR USE IN THE TREATMENT OF HEPATITIS B INFECTION | |
| BR112018069738A2 (en) | pharmaceutical composition, use of a hepatitis b virus nucleus antigen; and, method for immunoprophylaxis or immunotherapy against hepatitis b virus infection. | |
| MX2014014878A (en) | Combination of therapeutic agents for treating hcv infection. | |
| TH169455A (en) | Antibody component for the prevention or treatment of infection. Mutated hepatitis B | |
| Moattari et al. | Evaluation of measles, rubella, mumps, hepatitis B and varicella zoster antibodies in medical and dental students in Shiraz, Iran | |
| Ridruejo | biomarkers in HBV and prediction of treatment response | |
| Mushtaq et al. | Cigarette Smoke Extract (CSE) Increases Cytotoxicity By Pseudomonas Aeruginosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |